Scientific article
Meta-analysis
OA Policy
English

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Published inAnnals of the rheumatic diseases, vol. 72, no. 4, p. 583-589
Publication date2013
Abstract

Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

Keywords
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Antirheumatic Agents/therapeutic use
  • Arthritis, Juvenile/drug therapy/immunology
  • Arthritis, Rheumatoid/drug therapy/immunology
  • Consensus
  • Humans
  • Interleukin-6/antagonists & inhibitors/immunology
  • Spondylitis, Ankylosing/drug therapy/immunology
Citation (ISO format)
SCHOELS, Monika M et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. In: Annals of the rheumatic diseases, 2013, vol. 72, n° 4, p. 583–589. doi: 10.1136/annrheumdis-2012-202470
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN0003-4967
707views
546downloads

Technical informations

Creation31/07/2014 15:50:00
First validation31/07/2014 15:50:00
Update24/01/2025 14:36:19
Status update24/01/2025 14:36:19
Last indexation24/01/2025 14:44:14
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack